Mark P S Dunphy

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Association of vascular 18F-FDG uptake with vascular calcification
    Mark P S Dunphy
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 46:1278-84. 2005
  2. ncbi Molecular imaging of atherosclerosis
    Mark P S Dunphy
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room S 223A, New York, NY 10021, USA
    Curr Cardiol Rep 10:121-7. 2008
  3. ncbi In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research
    Mark P S Dunphy
    Sloan Kettering Institute for Cancer Research, 418 East 68th Street, New York, NY 10065, USA
    Microvasc Res 78:51-6. 2009
  4. ncbi Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging
    Mark P S Dunphy
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room H 214B, Box 77, New York, NY 10065, USA
    Mol Imaging Biol 14:25-31. 2012
  5. ncbi FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3598-605. 2012
  6. ncbi Radionuclide techniques for identifying vulnerable plaque
    Mark P S Dunphy
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 48:1753-5. 2007
  7. ncbi Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET
    Mark P S Dunphy
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 50:106S-21S. 2009

Collaborators

Detail Information

Publications7

  1. ncbi Association of vascular 18F-FDG uptake with vascular calcification
    Mark P S Dunphy
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 46:1278-84. 2005
    ..This investigation examines the geographic relationship of focal vascular (18)F-FDG uptake, as a marker of atherosclerotic inflammation, to arterial calcification detected by contemporaneous CT...
  2. ncbi Molecular imaging of atherosclerosis
    Mark P S Dunphy
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room S 223A, New York, NY 10021, USA
    Curr Cardiol Rep 10:121-7. 2008
    ..Molecular imaging can provide a "virtual histology" noninvasively about atherosclerotic disease, characterizing vascular lesions with markers of inflammation, angiogenesis, lipid metabolism, and more...
  3. ncbi In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research
    Mark P S Dunphy
    Sloan Kettering Institute for Cancer Research, 418 East 68th Street, New York, NY 10065, USA
    Microvasc Res 78:51-6. 2009
    ..To eliminate the variable of tumor heterogeneity from a novel in vivo model of tumor angiogenesis...
  4. ncbi Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging
    Mark P S Dunphy
    Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room H 214B, Box 77, New York, NY 10065, USA
    Mol Imaging Biol 14:25-31. 2012
    ..F-SKI-249380 is a first-of-its-kind PET tracer for imaging the in vivo pharmacokinetics of dasatinib, an investigational targeted therapy for solid malignancies...
  5. ncbi FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3598-605. 2012
    ....
  6. ncbi Radionuclide techniques for identifying vulnerable plaque
    Mark P S Dunphy
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 48:1753-5. 2007
  7. ncbi Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET
    Mark P S Dunphy
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 50:106S-21S. 2009
    ....